{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=114",
    "query": {
      "intervention": "Control Capsules",
      "page": 114
    },
    "page_size": 10
  },
  "pagination": {
    "page": 114,
    "page_size": 10,
    "total_count": 2912,
    "total_pages": 292,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=115&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=113&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-10T14:05:10.922Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04625595",
      "title": "Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type1 Diabetes"
      ],
      "interventions": [
        {
          "name": "350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule",
          "type": "DRUG"
        },
        {
          "name": "700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule",
          "type": "DRUG"
        },
        {
          "name": "1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule",
          "type": "DRUG"
        },
        {
          "name": "1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immunomolecular Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 30,
      "start_date": "2020-11-09",
      "completion_date": "2021-07-31",
      "has_results": false,
      "last_update_posted_date": "2021-08-25",
      "last_synced_at": "2026-11-10T14:05:10.922Z",
      "location_count": 3,
      "location_summary": "Chula Vista, California • Aurora, Colorado • Renton, Washington",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Renton",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04625595"
    },
    {
      "nct_id": "NCT00848172",
      "title": "Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Essential Tremor"
      ],
      "interventions": [
        {
          "name": "Octanoic Acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2009-02",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2012-12-27",
      "last_synced_at": "2026-11-10T14:05:10.922Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00848172"
    },
    {
      "nct_id": "NCT01318694",
      "title": "Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Alisporivir",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "ALV Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Debiopharm International SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 1081,
      "start_date": "2011-03",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2016-09-30",
      "last_synced_at": "2026-11-10T14:05:10.922Z",
      "location_count": 32,
      "location_summary": "Beverly Hills, California • Oakland, California • San Diego, California + 23 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01318694"
    },
    {
      "nct_id": "NCT04914377",
      "title": "To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "TQ Formula/Tab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novatek Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2021-06-08",
      "completion_date": "2022-01-01",
      "has_results": true,
      "last_update_posted_date": "2024-08-14",
      "last_synced_at": "2026-11-10T14:05:10.922Z",
      "location_count": 3,
      "location_summary": "San Diego, California • Hialeah, Florida • Houston, Texas",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04914377"
    },
    {
      "nct_id": "NCT05857930",
      "title": "A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Wheezing",
        "Wheezing Lower Respiratory Illness"
      ],
      "interventions": [
        {
          "name": "OM-85",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OM Pharma SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "72 Months",
        "sex": "ALL",
        "summary": "6 Months to 72 Months"
      },
      "enrollment_count": 296,
      "start_date": "2023-06-20",
      "completion_date": "2026-09-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-10T14:05:10.922Z",
      "location_count": 31,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05857930"
    },
    {
      "nct_id": "NCT00040677",
      "title": "A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Sickle Cell Anemia"
      ],
      "interventions": [
        {
          "name": "Low Dose ICA-17043",
          "type": "DRUG"
        },
        {
          "name": "High dose ICA-17043",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icagen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 90,
      "start_date": "2002-02",
      "completion_date": "2004-01",
      "has_results": false,
      "last_update_posted_date": "2011-07-18",
      "last_synced_at": "2026-11-10T14:05:10.922Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Oakland, California • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00040677"
    },
    {
      "nct_id": "NCT01674036",
      "title": "Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Genz-682452",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 63,
      "start_date": "2012-08",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2014-03-19",
      "last_synced_at": "2026-11-10T14:05:10.922Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01674036"
    },
    {
      "nct_id": "NCT04197986",
      "title": "Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Upper Tract Urothelial Carcinomas",
        "Urothelial Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Infigratinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QED Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2020-03-11",
      "completion_date": "2023-02-28",
      "has_results": true,
      "last_update_posted_date": "2024-03-13",
      "last_synced_at": "2026-11-10T14:05:10.922Z",
      "location_count": 47,
      "location_summary": "Tucson, Arizona • Duarte, California • Loma Linda, California + 39 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04197986"
    },
    {
      "nct_id": "NCT00737594",
      "title": "Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Portal Hypertension"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cobiprostone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sucampo Pharma Americas, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2008-07",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-11-10T14:05:10.922Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00737594"
    },
    {
      "nct_id": "NCT07209462",
      "title": "Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fragile X Syndrome"
      ],
      "interventions": [
        {
          "name": "Low dose of MRM-3379",
          "type": "DRUG"
        },
        {
          "name": "Middle Dose of MRM-3379",
          "type": "DRUG"
        },
        {
          "name": "High dose of MRM-3379",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Low dose of MRM-3379 Open-Label",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirum Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "13 Years to 45 Years · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2025-11-22",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-11-10T14:05:10.922Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Irvine, California • Orange, California + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07209462"
    }
  ]
}